To help prepare for the 2024-2025 Respiratory Syncytial Virus (RSV) season, we are excited to offer our Expert Series once again. This year, we are offering two 1-hour events featuring a 45-minute presentation followed by a 15-minute interactive Q&A about Beyfortus.
Join Beyfortus® Expert Series:
RSV LRTI Prevention for Infants
Beyfortus is the first and only long acting antibody indicated for the prevention of RSV lower respiratory tract disease in1:
- Neonates and infants born during or entering their first RSV season
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season
Each event will feature leading key opinion leaders (KOLs) from the RSV community with diverse backgrounds and experiences, including pediatricians, obstetricians and gynecologists (OB/GYNs), and nurses in both clinic and hospital settings. This live webinar format provides the opportunity to learn and interact with the leading experts about integrating Beyfortus into your practice.
Registration is now open for the following events:
Event 2: Implementing Beyfortus Into Clinical Practice on September 10th, 2024 at 6:00-7:00 PM ET, featuring:
.png)
Zubin Shah, MD, FAAP
- Neonatologist
- Baylor University Medical Center at Pediatrics Medical Group
- TX
Beyfortus Expert Series: RSV LRTI Prevention for Infants
We look forward to your participation!
LRTI, lower respiratory tract infection; OB/GYN, obstetrics and gynecology; RSV, respiratory syncytial virus
Important Safety Information
Reference: 1. Beyfortus (nirsevimab). Prescribing Information. Sanofi.
